Pancreatic neuroendocrine tumours (PanNETs) represent an uncommon type of pancreatic neoplasm, whose incidence is increasing worldwide. As per exocrine pancreatic cancer, a relationship seems to exist between PanNETs and glycaemic alterations. Diabetes mellitus (DM) or impaired glucose tolerance often occurs in PanNET patients as a consequence of hormonal hypersecretion by the tumour, specifically affecting glucose metabolism, or due to tumour mass effects. On the other hand, pre-existing DM may represent a risk factor for developing PanNETs and is likely to worsen the prognosis of such patients. Moreover, the surgical and/or pharmacological treatment of the tumour itself may impair glucose tolerance, as well as antidiabetic therapies may impact tumour behaviour and patients outcome. Differently from exocrine pancreatic tumours, few data are available for PanNETs as yet on this issue. In the present review, the bidirectional association between glycaemic disorders and PanNETs has been extensively examined, since the co-existence of both diseases in the same individual represents a further challenge for the clinical management of PanNETs.

Diabetes and pancreatic neuroendocrine tumours: which interplays, if any? / Gallo, Marco; Ruggeri, Rosaria Maddalena; Muscogiuri, Giovanna; Pizza, Genoveffa; Faggiano, Antongiulio; Colao, Annamaria. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - 67:(2018), pp. 1-9. [10.1016/j.ctrv.2018.04.013]

Diabetes and pancreatic neuroendocrine tumours: which interplays, if any?

Faggiano, Antongiulio;
2018

Abstract

Pancreatic neuroendocrine tumours (PanNETs) represent an uncommon type of pancreatic neoplasm, whose incidence is increasing worldwide. As per exocrine pancreatic cancer, a relationship seems to exist between PanNETs and glycaemic alterations. Diabetes mellitus (DM) or impaired glucose tolerance often occurs in PanNET patients as a consequence of hormonal hypersecretion by the tumour, specifically affecting glucose metabolism, or due to tumour mass effects. On the other hand, pre-existing DM may represent a risk factor for developing PanNETs and is likely to worsen the prognosis of such patients. Moreover, the surgical and/or pharmacological treatment of the tumour itself may impair glucose tolerance, as well as antidiabetic therapies may impact tumour behaviour and patients outcome. Differently from exocrine pancreatic tumours, few data are available for PanNETs as yet on this issue. In the present review, the bidirectional association between glycaemic disorders and PanNETs has been extensively examined, since the co-existence of both diseases in the same individual represents a further challenge for the clinical management of PanNETs.
2018
Diabetes; lifestyle; neuroendocrine tumours; nutrition; therapy; diabetes complications; diabetes mellitus; humans; hypoglycemic agents; neuroendocrine tumors; pancreatic neoplasms; prognosis; oncology; radiology; nuclear medicine and imaging
01 Pubblicazione su rivista::01a Articolo in rivista
Diabetes and pancreatic neuroendocrine tumours: which interplays, if any? / Gallo, Marco; Ruggeri, Rosaria Maddalena; Muscogiuri, Giovanna; Pizza, Genoveffa; Faggiano, Antongiulio; Colao, Annamaria. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - 67:(2018), pp. 1-9. [10.1016/j.ctrv.2018.04.013]
File allegati a questo prodotto
File Dimensione Formato  
Faggiano_Diabetes-and-tumours.pdf

accesso aperto

Tipologia: Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 313.89 kB
Formato Adobe PDF
313.89 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1298839
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 27
social impact